by Eric Christianson | Jan 22, 2023 | Cardiovascular Medication and Disease State Clinical Pearls
It is always controversial to come up with a top 5 list but we went for it. Below we have put together a list of the top 5 landmark trials in hyperlipidemia management. (NOTE: This is part of a bigger project that I am working on with Sarah Zahirudin, PharmD,...
by Eric Christianson | Nov 27, 2022 | Clinical Guideline Updates For Pharmacists
The Framingham risk score has been the primary method of determining a patient’s 10-year risk of cardiovascular disease. Scores such as this take into account a patient’s specific risk factors including age, gender, systolic blood pressure, total cholesterol,...
by Eric Christianson | Sep 26, 2021 | Medication and Disease State Clinical Pearls For Pharmacists
Ezetimibe (Zetia) is a medication used to lower cholesterol. More specifically, this medication is used in clinical practice to lower LDL and help get patients to a target goal. If you recall from your pharmacology classes, ezetimibe inhibits the absorption of...
by Eric Christianson | Mar 3, 2019 | Cardiovascular Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Statins are one of the most commonly prescribed medications to help reduce cholesterol and reduce the risk of cardiovascular events like heart attack and stroke. I’ve been asked the question a few different times about why we should choose a hydrophilic versus a...
by Eric Christianson | Jan 23, 2019 | Clinical Guideline Updates For Pharmacists
In late 2018, ACC and AHA came out with an update to their cholesterol guidelines. The last update was from 2013 so PCSK-9 inhibitors hadn’t even been approved at that time. Very High Risk Patients – My Biggest Takeaway I always had a hard time knowing...
